LAB/B: Solid EBITDA margin and free cash flow growth offset weak sales and currency headwinds

About this update from Genomma Lab Internacional Sab De Cv Class B

Q2 2025 saw modest sales growth, strong EBITDA margin expansion, and a 65% increase in free cash flow, despite currency headwinds and a weak beverage season in Mexico. Outlook for 2025 is cautious, but gradual growth is expected in 2026, supported by innovation, distribution expansion, and digital initiatives. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genomma Lab Internacional Sab De Cv Class B